Clinical Effect Observation of Tiotropium Bromide for Patients with Chronic Obstructive Pulmonary Disease at Stable Stage
Objective To analyze clinical effect of tiotropium bromide for chronic obstructive pulmonary disease(COPD)at stable stage.Methods The paper chose 100 stable COPD patients in our hospital from April 2017 to March 2023,and divided them into control group and observation group randomly,with 50 cases in each group.Control group was treated with routine treatment,while observation group with routine treatment combined with tiotropium bromide.Difference in lung function,serum markers,chronic obstructive pulmonary disease assessment questionnaire(CAT)scores,respiratory distress severity grading scores(MRC),and 6-minute walking distance(6MWD)was compared between two groups.Results Before treatment,there was no statistically significant difference in lung function indicators,serum markers,CAT scores,MRC scores,and 6MWD scores between the groups(P>0.05).After treatment,forced vital capacity(FVC),forced expiratory volume at 1 second(FEV1),and FEV1/FVC in observation group was higher than control group(P<0.05).After treatment,serum levels of matrix metalloproteinase-9(MMP-9),surfactant protein D(SP-D),and interleukin-17(IL-17)in observation group were lower than control group(P<0.05).After treatment,CAT and MRC scores in observation group were lower than control group,and level of 6MWD was higher than control group(P<0.05).Conclusion The introduction of tiotropium bromide as a therapeutic tool in the stable phase of COPD treatment can significantly improve the clinical therapeutic effect of patients,optimise their lung function and effectively inhibit the inflammatory response,thus reducing the symptoms of dyspnoea.The mechanism of action of this treatment is related to the regulation of MMP-9 and SP-D levels.
NETL
NSTL
万方数据
